Journal
ELIFE
Volume 7, Issue -, Pages -Publisher
ELIFE SCIENCES PUBLICATIONS LTD
DOI: 10.7554/eLife.32952
Keywords
-
Categories
Funding
- Department of Biotechnology, Ministry of Science and Technology [BRB/10/1294/2014, MED/30/1454/2014]
- Department of Biotechnology, Ministry of Science and Technology
- Department of Science and Technology, Ministry of Science and Technology [EMR/2014/000065]
- Council of Scientific and Industrial Research [37(1646)/15/EMR-II]
- Department of Science and Technology, Ministry of Science and Technology
Ask authors/readers for more resources
Glycogen synthase kinase 3 (GSK3) is a critical regulator of diverse cellular functions involved in the maintenance of structure and function. Enzymatic activity of GSK3 is inhibited by N-terminal serine phosphorylation. However, alternate post-translational mechanism(s) responsible for GSK3 inactivation are not characterized. Here, we report that GSK3 alpha and GSK3 beta are acetylated at Lys246 and Lys183, respectively. Molecular modeling and/or molecular dynamics simulations indicate that acetylation of GSK3 isoforms would hinder both the adenosine binding and prevent stable interactions of the negatively charged phosphates. We found that SIRT2 deacetylates GSK3 beta, and thus enhances its binding to ATP. Interestingly, the reduced activity of GSK3 beta is associated with lysine acetylation, but not with phosphorylation at Ser9 in hearts of SIRT2-deficient mice. Moreover, GSK3 is required for the anti-hypertrophic function of SIRT2 in cardiomyocytes. Overall, our study identified lysine acetylation as a novel post-translational modification regulating GSK3 activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available